United Arab Emirates Antiviral Drug Market Size & Outlook, 2026-2034
United Arab Emirates Antiviral Drug Market Insights
- As highlighted in Packaging Market Insights analysis, the United Arab Emirates Antiviral Drug Market, worth USD 2172.05 Million in 2025, is forecasted to achieve USD 3882.77 Million by 2034.
- The United Arab Emirates market is anticipated to grow at a CAGR of 6.66% during the period 2026–2034.
- By 2025, DNA Polymerase Inhibitors represented the largest share of the Drug Class market size.
- DNA Polymerase Inhibitors is expected to remain the key growth driver within Drug Class, registering the fastest CAGR during the forecast period.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, United Arab Emirates held 3.38% of the global Antiviral Drug Market size.
- By 2034, United States is anticipated to capture the largest share of the global Antiviral Drug Market.
- In Middle East and Africa, United Arab Emirates is expected to lead the regional Antiviral Drug Market size by 2034.
- United Arab Emirates will remain the fastest-growing market in Middle East and Africa, reaching USD 3880.49 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 2172.05 Million |
| Market Size In 2034 | USD 3882.77 Million |
| Largest segment | DNA Polymerase Inhibitors |
| Units | Revenue in USD Million |
| CAGR | 6.66% (2026-2034) |
| Segmnetation Covered | |
| Drug Class |
|
| Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Arab Emirates Antiviral Drug Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Polymerase Inhibitors | XX.x | XX.x | XX.x | 1053.88 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reverse Transcriptase Inhibitors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Protease Inhibitors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
United Arab Emirates Antiviral Drug Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV | XX.x | XX.x | XX.x | 986.12 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hepatitis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Influenza | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.